Traders purchased shares of Amgen (NASDAQ:AMGN) on weakness during trading hours on Thursday. $102.44 million flowed into the stock on the tick-up and $65.46 million flowed out of the stock on the tick-down, for a money net flow of $36.98 million into the stock. Of all companies tracked, Amgen had the 25th highest net in-flow for the day. Amgen traded down ($2.18) for the day and closed at $172.93
Several equities research analysts have recently weighed in on AMGN shares. Mizuho set a $192.00 price objective on Amgen and gave the company a “buy” rating in a research note on Friday, December 22nd. Piper Jaffray reiterated a “buy” rating on shares of Amgen in a research note on Tuesday, January 2nd. Vetr lowered Amgen from a “buy” rating to a “hold” rating and set a $184.25 price objective on the stock. in a research note on Wednesday, January 3rd. Oppenheimer set a $205.00 price objective on Amgen and gave the company a “buy” rating in a research note on Friday, January 5th. Finally, BidaskClub upgraded Amgen from a “sell” rating to a “hold” rating in a research note on Thursday, January 18th. Two research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and ten have issued a buy rating to the stock. Amgen presently has a consensus rating of “Hold” and an average target price of $190.57.
The stock has a market cap of $115,564.02, a P/E ratio of 13.64, a price-to-earnings-growth ratio of 2.12 and a beta of 1.36. The company has a debt-to-equity ratio of 1.35, a current ratio of 5.49 and a quick ratio of 5.17.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, February 1st. The medical research company reported $2.89 EPS for the quarter, missing the Zacks’ consensus estimate of $3.03 by ($0.14). The firm had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.84 billion. Amgen had a net margin of 8.66% and a return on equity of 30.87%. The firm’s quarterly revenue was down 2.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.89 earnings per share. equities analysts expect that Amgen will post 13.28 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 8th. Shareholders of record on Thursday, May 17th will be given a $1.32 dividend. The ex-dividend date is Wednesday, May 16th. This represents a $5.28 dividend on an annualized basis and a yield of 3.08%. Amgen’s payout ratio is 41.97%.
Amgen declared that its Board of Directors has approved a share buyback plan on Thursday, February 1st that permits the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization permits the medical research company to purchase shares of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board believes its shares are undervalued.
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the stock in a transaction on Friday, March 16th. The stock was sold at an average price of $189.75, for a total value of $289,368.75. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold a total of 4,575 shares of company stock worth $818,330 over the last quarter. Corporate insiders own 0.19% of the company’s stock.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Janus Henderson Group PLC lifted its stake in shares of Amgen by 3,664.7% in the 2nd quarter. Janus Henderson Group PLC now owns 3,699,351 shares of the medical research company’s stock valued at $637,139,000 after purchasing an additional 3,601,087 shares during the period. FMR LLC lifted its stake in shares of Amgen by 4.8% in the 2nd quarter. FMR LLC now owns 56,999,572 shares of the medical research company’s stock valued at $9,817,037,000 after purchasing an additional 2,587,041 shares during the period. Amundi Pioneer Asset Management Inc. lifted its stake in shares of Amgen by 382.3% in the 4th quarter. Amundi Pioneer Asset Management Inc. now owns 1,389,775 shares of the medical research company’s stock valued at $241,682,000 after purchasing an additional 1,101,649 shares during the period. Renaissance Technologies LLC lifted its stake in shares of Amgen by 40.9% in the 2nd quarter. Renaissance Technologies LLC now owns 3,400,145 shares of the medical research company’s stock valued at $585,607,000 after purchasing an additional 986,700 shares during the period. Finally, Nordea Investment Management AB lifted its stake in shares of Amgen by 12.9% in the 2nd quarter. Nordea Investment Management AB now owns 7,040,599 shares of the medical research company’s stock valued at $1,212,602,000 after purchasing an additional 806,119 shares during the period. Hedge funds and other institutional investors own 79.54% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Investors Buy Amgen (AMGN) on Weakness” was originally published by Macon Daily and is the sole property of of Macon Daily. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://macondaily.com/2018/04/21/investors-buy-amgen-amgn-on-weakness.html.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.